Skip to main content Back to Top
Advertisement

2/14/2020

Lidocaine with Epinephrine Injection

Products Affected - Description

    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 1%, 30 mL vial, 100 count, NDC 00409-3178-02
    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 2%, 20 mL vial, 100 count, NDC 00409-3182-01
    • Lidocaine (with epinephrine 1:200,000) injection, Pfizer, 1.5%, 30 mL vial, 25 count, NDC 00409-3181-01
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 20 mL vial, 25 count, NDC 63323-0482-27
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 10 mL vial, 25 count, NDC 63323-0487-17
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 30 mL vial, sterile-pack 5 count, NDC 63323-0487-31
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 30 mL vial, 25 count, NDC 63323-0487-37
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1.5%, 30 mL vial, sterile-pack 5 count, NDC 63323-0488-31
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 2%, 10 mL vial, 25 count, NDC 63323-0489-17
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 2%, 20 mL vial, sterile-pack 5 count, NDC 63323-0489-21
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 2%, 20 mL vial, 25 count, NDC 63323-0489-27

Reason for the Shortage

    • Fresenius Kabi has Xylocaine with epinephrine presentations on shortage due to increased demand for the product and manufacturing delays.
    • Pfizer has lidocaine with epinephrine presentations on shortage due to manufacturing delays.

Available Products

    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 1%, 20 mL vial, 100 count, NDC 00409-3178-01
    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 1%, 50 mL vial, 100 count, NDC 00409-3178-03
    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 2%, 30 mL vial, 100 count, NDC 00409-3182-02
    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 2%, 50 mL vial, 100 count, NDC 00409-3182-03
    • Lidocaine (with epinephrine 1:200,000) injection, Pfizer, 0.5%, 50 mL vial, 100 count, NDC 00409-3177-01
    • Lidocaine (with epinephrine 1:200,000) injection, Pfizer, 1.5%, 5 mL glass ampule, 10 count, NDC 00409-1209-01
    • Lidocaine (with epinephrine 1:200,000) injection, Pfizer, 2%, 20 mL vial, 25 count, NDC 00409-3183-01
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.5%, 50 mL vial, 25 count, NDC 63323-0481-57
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 10 mL vial, 25 count, NDC 63323-0482-17
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 50 mL vial, 25 count, NDC 63323-0482-57
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 2%, 20 mL vial, 25 count, NDC 63323-0483-27
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 2%, 50 mL vial, 25 count, NDC 63323-0483-57
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1.5%, 10 mL vial, 25 count, NDC 63323-0488-17
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1.5%, 30 mL vial, 25 count, NDC 63323-0488-37

Estimated Resupply Dates

    • Fresenius Kabi has 1% Xylocaine with epinephrine (1:200,000) 20 mL vials are on back order and the company estimates release dates of late-February 2020. The 1% Xylocaine-MPF with epinephrine (1:200,000) 10 mL vials are on back order and the company estimates release dates of late-February 2020. The 1% Xylocaine-MPF with epinephrine (1:200,000) 30 mL vials are on back order and the company estimates a release date of mid-March 2020. The 1% Xylocaine-MPF with epinephrine (1:200,000) 30 mL vials in sterile packs are on back order and the company cannot estimate a release date. The 1.5% Xylocaine-MPF with epinephrine (1:200,000) 30 mL vials in sterile packs are on back order and the company cannot estimate a release date. The 2% Xylocaine-MPF with epinephrine (1:200,000) 10 mL vials are on back order and the company estimates a release date of mid-February 2020. The 2% Xylocaine-MPF with epinephrine (1:200,000) 20 mL vials are on back order and the company cannot estimate a release date. The 2% Xylocaine-MPF with epinephrine (1:200,000) 20 mL vials in sterile packs are on back order and the company cannot estimate a release date. Check wholesalers for inventory.
    • Pfizer has 1% lidocaine with epinephrine (1:100,000) 30 mL vials available in limited supply. The 1.5% lidocaine with epinephrine (1:200,000) 30 mL vials are available in limited supply. The 2% lidocaine with epinephrine (1:100,000) 20 mL vials are on back order and the company estimates a release date of February 2020.

Updated

Updated February 14, 2020 by Stephen Andrews, PharmD, BCPS, Drug Information Specialist. Created November 16, 2011 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins